1. Netherlands Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Onward Medical N.V.

Onward Medical N.V.

2.71
USD
-0.14
(-4.91%)
209.93MMarket Cap
Mar 03Next Earn
Onward Medical N.V.
OTC:ONWRF
(OTC Markets)

Recent

price

2.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
- -
- -
- -
- -
- -
- -
- -
0.01
0.08
- -
Revenue per Share
- -
-1.68
-2.29
-3.39
-3.62
-1.09
-1.2
-0.8
-0.9
- -
Basic EPS, GAAP
- -
-1.23
-1.69
-2.22
-2.34
-0.9
-1.08
-0.72
-0.85
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.13
-0.34
-0.5
-1.08
2.74
1.74
0.59
1.08
0.99
1.03
Book Value per Share
-0.13
-0.35
-0.75
-1.31
2.41
1.41
0.27
0.84
0.83
0.91
Tangible Book Value per Share
30
6
6
6
9
30
30
45
47
57
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
4
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-30,796.15
-52,151.47
-15,223.58
-1,082.43
- -
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
1
- -
Depreciation Expense
- -
-10
-13
-20
-34
-33
-36
-36
-42
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-31,511.54
-53,207.35
-15,600.44
-1,105.48
- -
Profit Margin (%)
6
7
13
4
87
56
25
54
63
80
Working Capital
11
17
34
42
13
14
16
14
13
14
LT Debt
-4
-10
-15
-32
83
53
18
48
55
72
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-48.44
-102.55
-108.28
-80.85
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
1
- -
LT Borrowings
14
13
14
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
56
70
Market Capitalization
195
272
184

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
45
74
90
Cash, Cash Equivalents & STI
41
68
82
Accounts Receivable, Net
- -
1
2
Inventories
- -
1
1
Total Current Liabilities
10
11
10
Payables & Accruals
- -
- -
- -
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-55.36%
15.11%
Free Cash Flow
- -
26.78%
23.77%
Net Income, GAAP
- -
18.61%
16.97%
Sales/Revenue/Turnover
- -
- -
1,550.66%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
4
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.8
2025
- -
- -
-0.9
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Onward Medical N.V. is a medical technology company specializing in developing and commercializing innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities. The company offers its core products and services through technology platforms based on ARC Therapy, which delivers targeted, programmed electrical stimulation of the spinal cord. This therapy is provided via the external ARC-EX® System designed to enhance hand strength and sensation, the implantable ARC-IM® System targeting blood pressure instability and other symptoms, and the ARC-BCI™ platform, which integrates brain-computer interface technology for thought-driven movement restoration. Onward Medical operates across multiple regions including France, Germany, the Netherlands, the United Kingdom, and Switzerland, supported by academic and clinical partnerships. Founded in 2014, the company is headquartered in Eindhoven, the Netherlands, and maintains a Science and Engineering Center in Lausanne, Switzerland. Recent major developments include a successful private placement in October 2025 raising over EUR 50 million to advance commercial activities for the ARC-EX System and to prepare the global pivotal Empower BP study for the implantable ARC-IM System. The ARC-EX System received FDA 510(k) clearance for home use in the U.S., expanding its market opportunity, while the ARC-IM System received an FDA Investigational Device Exemption to initiate the Empower BP pivotal clinical trial targeting blood pressure instability after SCI. In Q3 2025, the company sold 40 ARC-EX Systems and achieved revenue exceeding EUR 1 million for the first time, alongside progress in clinical feasibility studies and scientific publications highlighting therapeutic advances. ONWARD Medical’s technology continues to be recognized with multiple FDA Breakthrough Device Designations, underscoring its leadership in spinal cord injury neurotechnology and therapy innovation.